1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassium salt

BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation)[1].

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

Ki: 1.5 nM (CrtM). IC50: 100-300 nM (S. aureus pigment formation)[1].

BPH-652 treatment (0.5 mg twice per day (days −1, 0, 1, and 2), Intraperitoneal injection) significantly lowers S. aureus bacterial counts in the kidneys of the mice than those of the control group (P < 0.001), with 8 of 13 below the detection threshold, versus only 2 of 14 in the control group; on average, this result corresponds to a 98% decrease in surviving bacteria in the treatment group[1]. Animal Model: A systemic S. aureus infection model in mice[1]. Dosage: 0.5 mg twice per day (days −1, 0, 1, and 2). Administration: Intraperitoneal injection. Result: S. aureus bacterial counts in the kidneys of the mice treated with BPH-652 were significantly lower than those of the control group.

[1]. Liu CI, et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science. 2008 Mar 7;319(5868):1391-4.